2
Clinical Trials associated with Anti-CD19 CAR-T cell therapy(Aikangd Biomedical Technology (Suzhou) Co Ltd)Clinical study of CAR-T immune cell targeted therapy for recurrent/refractory CD19+ leukemia and lymphoma
Humanized CAR-T Therapy for Treatment of Recurrent or Refractory B Cell Malignancy by Targeting CD19
The present study evaluates the safety and efficacy of humanized Chimeric antigen receptor T cells (CAR-T) in treating recurrent or refractory B cell malignancy targeting CD19 with a humanized scFv. All participants will receive autologous chimeric antigen receptor engineered T cells.
100 Clinical Results associated with Anti-CD19 CAR-T cell therapy(Aikangd Biomedical Technology (Suzhou) Co Ltd)
100 Translational Medicine associated with Anti-CD19 CAR-T cell therapy(Aikangd Biomedical Technology (Suzhou) Co Ltd)
100 Patents (Medical) associated with Anti-CD19 CAR-T cell therapy(Aikangd Biomedical Technology (Suzhou) Co Ltd)
100 Deals associated with Anti-CD19 CAR-T cell therapy(Aikangd Biomedical Technology (Suzhou) Co Ltd)